表紙
市場調査レポート

世界の創薬アウトソーシング市場の予測

Drug Discovery Outsourcing Market Forecast 2015-2025: Opportunities for Leading Companies

発行 Visiongain Ltd 商品コード 260308
出版日 ページ情報 英文 223 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=134.78円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。
制限内容は、上記ライセンスの[?]アイコンをクリックしてご確認ください。

Back to Top
世界の創薬アウトソーシング市場の予測 Drug Discovery Outsourcing Market Forecast 2015-2025: Opportunities for Leading Companies
出版日: 2015年03月19日 ページ情報: 英文 223 Pages
概要

2015年における世界の創薬アウトソーシング市場の収益規模は166億ドルの規模に達すると予測されています。企業がコスト削減のために海外進出するために市場はグル―バル化が進み、新興国に拠点を置くCRO(受託臨床試験機関)に対する需要が更なる市場成長促進因子となっています。また、初期の創薬段階において製薬会社やバイオテクノロジー企業がCROと提携して開発に取り組む傾向が強まっています。

当レポートは、世界の創薬アウトソーシング市場の現状と見通しについて調査分析し、創薬業務をアウトソーシングする理由とメリット、主なCRO(受託臨床試験機関)のプロファイル、業務区分・地域/国別の収益予測、創薬アウトソーシングの成長推進因子・阻害因子の分析、専門家による見解、SWOT分析などをまとめてお届けいたします。

第1章 レポート概要

第2章 創薬アウトソーシング:イントロダクション

  • アウトソーシングとは?
  • 創薬アウトソーシングとは?
  • 創薬業務をアウトソーシングする理由
  • 創薬における典型的なアウトソーシングプロセス(産学協同を含む)
  • 創薬のアウトソースモデルが革新を増進
  • 創薬におけるアウトソーシングプロセス
  • 創薬のアウトソーシングにおける課題
  • CROに人気の新興市場
  • 最新の創薬アウトソーシング提携
  • 創薬アウトソーシング関連用語集

第3章 世界の創薬アウトソーシング市場

  • 創薬アウトソーシング:世界市場の概要
  • 世界の創薬アウトソーシング市場の部門
  • 世界の創薬アウトソーシング市場:実績と予測(部門別)
  • 世界の化学関連サービスのアウトソーシング市場
    • 実績
    • 市場予測
  • 世界のバイオロジー関連サービスのアウトソーシング市場
    • 実績
    • 市場予測
  • 世界のリード最適化のアウトソーシング市場
    • 実績
    • 市場予測
  • 世界のリード化合物の特定・スクリーニングのアウトソーシング市場
    • 実績
    • 市場予測

第4章 主要国市場

  • 創薬アウトソーシングの概要
  • 主要国市場:実績と予測
  • 市場シェア予測
  • CAGR予測
  • 市場売上予測
  • EU5ヶ国:市場売上予測(地域別)
  • 日本:市場売上予測
  • 中国:市場売上予測
  • インド:市場売上予測
  • ブラジル:市場売上予測
  • ロシア:市場売上予測
  • 韓国:市場売上予測
  • メキシコ:市場売上予測
  • その他の国:市場売上予測

第5章 創薬サービスを提供する主要企業

  • 創薬アウトソーシング:分裂し、拡大する市場
  • 主要開発業務受託機関の特徴
  • 主要国の提供するサービス
  • Albany Molecular Research, Inc (AMRI)
  • Aptuit
  • Charles River Laboratories
  • Covance
  • Cyprotex
  • Domainex:有望なパイプライン製品
  • Evotec
  • GenScript
  • Quintiles
  • Selcia
  • Viva Biotech
  • WIL Research Laboratories
  • WuXi AppTec

第6章 創薬アウトソーシング市場:定性分析

  • 市場成長促進因子および抑制因子
  • SWOT分析
  • 強み
  • 弱み
  • 機会
  • 脅威
  • ポーターのファイブフォース分析

第7章 専門家の見解

第8章 総論

  • 市場概要
  • リード最適化―最速成長部門
  • 新興市場の台頭
  • アライアンス・コラボレーションが引き続き
  • 終わりに

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: PHA0036

Drug discovery outsourcing - your guide to the commercial potential of services and companies in this market

Where is the drug discovery outsourcing market heading? Visiongain's new report gives you revenue predictions for the drug discovery outsourcing market and its submarkets from 2015 to 2025, helping you stay ahead.

Our new 223-page report provides 149 tables, charts, and graphs. Discover the growing trends of this industry. In particular, our new study lets you assess forecasted sales at overall world market and national level. You will see financial results, drivers and restraints, and revenue predictions.

Besides revenue forecast to 2025, this report provides you with market shares, business outlooks, qualitative analyses (including SWOT and Porter's Five Forces Analysis), company profiles and commercial partnerships. Also, read the full transcript of three exclusive expert opinion interviews to inform you about prospects for investments and sales:

  • Dr. Mario Polywka, Chief Operating Officer, Evotec
  • Dr. John Davis, Director of Discovery & Dave Roberts, Business Development Director, Radiochemistry, Selcia
  • Dr. Paul Overton, Executive VP, Business Development & Marketing, Apuit

See revenue forecasts for leading drug discovery outsourcing sectors

Along with prediction of overall world market value to 2025, our report shows you revenue forecasting for the four services sectors at world level:

  • Chemistry services market forecast 2015-2025
  • Biology services market forecast 2015-2025
  • Lead optimisation market forecast 2015-2025
  • Lead identification and screening market forecast 2015-2025

The analysis helps you identify market potential with individual revenue forecasts, annual growth rates and CAGRs and market shares.

Discover prospects of the leading national markets for the drug discovery outsourcing

The drug discovery outsourcing market is becoming increasingly global as companies look to lower costs by off-shoring their work to CROs based in emerging economies.

You will discover individual revenue forecasts, annual growth rates, CAGRs, and market shares to 2025, as well as written supporting analyses for each of the 13 leading national markets and the rest of the world (RoW):

  • US
  • Japan
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • China
  • Brazil
  • Russia
  • India
  • South Korea
  • Mexico
  • Rest of the World

Demand for CROs based in emerging markets will be a major driver of growth in this market.

Leading companies and potential for market growth

Our new study predicts the world market for drug discovery outsourcing will reach $16.6bn in 2015. There is the increasing trend for pharmaceutical and biotech companies to form partnerships and alliances with CROs during the early drug discovery phase.

Our research profiles leading companies, assessing their financial performance and products. You will see which organisations hold the greatest potential and what services each offer. See the profiles of 14 leading companies:

  • Albany Molecular Research (AMRI)
  • Aptuit
  • Charles River Laboratories (Acquired Galapagos CRO in 2014)
  • Covance (Acquired by LabCorp in 2015)
  • Cyprotex
  • Domainex
  • Evotec
  • GenScript
  • Pharmaceutical Product Development (PPD)
  • Quintiles
  • Selcia
  • Viva Biotech
  • WIL Research Laboratories
  • WuXi AppTec

In general, a company profile gives you the following information:

  • Drug discovery revenue forecast from 2015 to 2025
  • Historical and recent revenue figures
  • Description of services and products
  • Assessment of recent developments - mergers and acquisitions (M&A), collaborations, partnerships and alliances

Discover capabilities, progress, and commercial prospects, helping you stay ahead.

How the Drug Discovery Outsourcing Market Forecast 2015-2025: Opportunities for Leading Companies report delivers

In summary, our 223-page report gives you the following knowledge:

  • Revenue forecast to 2025 for the world drug discovery outsourcing market and 4 leading submarkets - Discover the industry's prospects, finding promising areas for investment and revenues.
  • Revenue forecasts to 2025 for the leading 13 national markets - US, Japan, Germany, France, UK, Italy, Spain, Brazil, Russia, China, India, South Korea, Mexico and the Rest of the World
  • Assessment of 14 leading companies - hear about collaborations, partnerships, contracts and alliances and predicted revenues to 2025
  • Analysis of what stimulates and restrains that industry and market - assess challenges and strengths, helping you compete and get advantages.
  • View opinions from our survey, seeing interviews with leading drug discovery outsourcing experts.

You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else

With our study you are less likely to fall behind in knowledge or miss opportunities. See how you could benefit your research, analyses, and decisions.

Visiongain's study is for everybody needing commercial analyses for the drug discovery outsourcing market and leading CROs that offer these services. You find data, trends and predictions. Please order our report now.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. The Drug Discovery Outsourcing Market Overview
  • 1.2. Drug Discovery Outsourcing Market Segmentation
  • 1.3. Why You Should Read This Report
  • 1.4. How This Report Delivers
  • 1.5. Key Questions Answered by This Analytical Report
  • 1.6. Who is This Report For?
  • 1.7. Methodology
  • 1.8. Frequently Asked Questions (FAQ)
  • 1.9. Associated Reports

2. An Introduction to Drug Discovery Outsourcing

  • 2.1. What is Outsourcing?
  • 2.2. What is Drug Discovery Outsourcing?
  • 2.3. Why Outsource Drug Discovery?
  • 2.4. A Common Drug Discovery Model Includes Pharma Collaborations with Academia
  • 2.5. The Outsource Model for Drug Development Increases Innovation
  • 2.6. Outsourced Processes in Drug Discovery
  • 2.7. Challenges with Drug Discovery Outsourcing
  • 2.8. Emerging Markets are a Popular Destination for CROs
  • 2.9. Strategic Partnerships to Acquisitions
  • 2.10. Recent Drug Development Outsourcing Agreements
  • 2.11. Glossary of Terms Related to Drug Discovery Outsourcing

3. Global Drug Discovery Outsourcing Market and Service Area Submarkets, 2015-2025

  • 3.1. Drug Discovery Outsourcing: Global Market Overview
  • 3.2. The Global Drug Discovery Outsourcing Market Sectors
  • 3.3. The Global Drug Discovery Outsourcing Market by Sector, 2014
  • 3.4. The Global Drug Discovery Outsourcing Market by Sector, 2015-2025
  • 3.5. The Changing Market Shares by Sector, 2015-2025
  • 3.6. The Global Chemistry Services Outsourcing Market, 2014
    • 3.6.1. Libraries
    • 3.6.2. Building Blocks
    • 3.6.3. Compound Synthesis
    • 3.6.4. The Global Chemistry Services Outsourcing Market Forecast, 2015-2025
  • 3.7. The Global Biology Services Outsourcing Market, 2014
    • 3.7.1. Target Identification
    • 3.7.2. Target Validation
    • 3.7.3. The Global Biology Services Outsourcing Market Forecast, 2015-2025
  • 3.8. The Global Lead Optimisation Market, 2014
    • 3.8.1. ADMET Screening: Prevents Late Stage Failure of Clinical Trials
    • 3.8.2. The Global Lead Optimisation Market Forecast, 2015-2025
  • 3.9. The Global Lead Identification and Screening Outsourcing Market, 2014
    • 3.9.1. Methods of Screening in Drug Discovery
    • 3.9.2. Primary Screening
    • 3.9.3. The Global Lead Identification and Screening Outsourcing Market Forecast, 2015-2025

4. The Leading National Markets in the Drug Discovery Outsourcing Markets 2015-2025

  • 4.1. Drug Discovery Outsourcing Overview
  • 4.2. The Leading National Markets in the Drug Discovery Outsourcing Market, 2014
  • 4.3. The Leading National Markets in the Drug Discovery Outsourcing Market, 2015-2025
  • 4.4. The Changing Market Shares of the Leading National Markets in the Drug Discovery Outsourcing Market, 2015-2025
  • 4.5. CAGRS of the Leading National Markets in the Drug Discovery Outsourcing Market, 2015-2025
  • 4.6. The US Drug Discovery Outsourcing Market Sales Forecast, 2015-2025
  • 4.7. The EU5 Drug Discovery Outsourcing Market by Region, 2014
    • 4.7.1. The EU5 Drug Discovery Outsourcing Market Forecast, 2015-2025
    • 4.7.2. CAGRS by EU5 Region, 2015-2025
    • 4.7.3. The EU5 Changing Market Shares by Country 2015-2025
      • 4.7.3.1. The German Drug Discovery Outsourcing Market Sales Forecast, 2015-2025
      • 4.7.3.2. The UK Drug Discovery Outsourcing Market Sales Forecast, 2015-2025
      • 4.7.3.3. The French Drug Discovery Outsourcing Market Sales Forecast, 2015-2025
      • 4.7.3.4. The Italian Drug Discovery Outsourcing Market Sales Forecast, 2015-2025
      • 4.7.3.5. The Spanish Drug Discovery Outsourcing Market Sales Forecast, 2015-2025
  • 4.8. The Japanese Drug Discovery Outsourcing Market Sales Forecast, 2015-2025
  • 4.9. The Chinese Drug Discovery Outsourcing Market Sales Forecast, 2015-2025
    • 4.9.1. Challenges to China's Growth
  • 4.10. The Indian Drug Discovery Outsourcing Market Sales Forecast, 2015-2025
  • 4.11. The Brazilian Drug Discovery Outsourcing Market Sales Forecast, 2015-2025
  • 4.12. The Russian Drug Discovery Outsourcing Market Sales Forecast, 2015-2025
  • 4.13. The South Korean Drug Discovery Outsourcing Market Sales Forecast, 2015-2025
  • 4.14. The Mexican Drug Discovery Outsourcing Market Sales Forecast, 2015-2025
  • 4.15. The Rest of the World Drug Discovery Outsourcing Market Sales Forecast, 2015-2025

5. Leading Companies in the Drug Discovery Outsourcing Market in 2015

  • 5.1. Drug Discovery Outsourcing: A Fragmented and Growing Marketplace
  • 5.2. Characteristics of Leading Contract Research Organisations
    • 5.2.1. A Highly Quality Workforce
    • 5.2.2. Emphasis on Intellectual Property Protection
    • 5.2.3. Long Term Working Relationship
    • 5.2.4. Success in Project Completion
    • 5.2.5. Internal Drug Discovery Programmes
  • 5.3. Service Offerings of Leading Companies in the Drug Discovery Outsourcing Market
  • 5.4. Albany Molecular Research (AMRI)
    • 5.4.1. Sales and Recent Financial Performance, 2011-2013
    • 5.4.2. AMRI's Drug Discovery Services
    • 5.4.3. Internal Portfolio of Drug Discovery and Development Programme Collaborations
  • 5.5. Aptuit
    • 5.5.1. INDIGO: Accelerating Early Drug Candidates
    • 5.5.2. Aptuit Clinical Trial Supplies
    • 5.5.3. Strategic Partnerships, Acquisitions and Divestitures
      • 5.5.3.1. Divestiture of Aseptic Clinical Manufacturing
      • 5.5.3.2. Aptuit's Extended Partnership with GSK for Verona Centre
      • 5.5.3.3. Partnership with Siena Biotech
      • 5.5.3.4. Partnership with Laurus Labs
  • 5.6. Charles River Laboratories
    • 5.6.1. Sales and Recent Financial Performance, 2011-2013
    • 5.6.2. Charles River Laboratories: An External Acquisition Strategy
      • 5.6.2.1. Acquisition of ChanTest
      • 5.6.2.2. Acquisition of Galapagos' CRO Services Division (BioFocus and Argenta)
      • 5.6.2.3. Acquisition of VivoPath
    • 5.6.3. Charles River Laboratories: Revenue and Financial Analysis, 2014
      • 5.6.3.1. Charles River Laboratories: Financial Performance by Business Segment, 2013-2014
    • 5.6.4. Charles River Laboratories Sales Forecast, 2015-2025
  • 5.7. Covance (Acquired by LabCorp)
    • 5.7.1. Covance: Historical Revenue and Financial Performance, 2010-2013
    • 5.7.2. Covance: Early Stage Discovery Efforts
    • 5.7.3. Agreement with Sanofi
    • 5.7.4. Agreement with Kellogg Company
    • 5.7.5. Agreement with BioPontis Alliance
    • 5.7.6. Agreement with Indiana Clinical and Translational Sciences Institute (CTSI)
    • 5.7.7. Agreement with Eli Lilly
  • 5.8. Cyprotex
    • 5.8.1. Historical Revenue and Financial Performance, 2011-2013
    • 5.8.2. Cyprotex: Revenue by Region, 2013
    • 5.8.3. Cyprotex: Revenue Analysis and Forecast 2015-2025
  • 5.9. Domainex
    • 5.9.1. Drug Pipeline
    • 5.9.2. TBK1/ IKKε Inhibitors
    • 5.9.3. Methyltransferase (KMTS) Inhibitors
  • 5.10. Evotec
    • 5.10.1. Strategic Action Plan
    • 5.10.2. Evotec: Revenue and Financial Analysis, 2010-2013
    • 5.10.3. EVT Integrate and EVT Innovate
    • 5.10.4. Partnerships with Pharma for Drug Discovery
      • 5.10.4.1. Partnership with Sanofi
      • 5.10.4.2. Extended Partnership with Evotec
      • 5.10.4.3. Partnership with Johnson & Johnson
      • 5.10.4.4. Partnership with AstraZeneca
      • 5.10.4.5. Partnership with Bayer Pharma
      • 5.10.4.6. Partnership with Boehringer Ingelheim Pharma
      • 5.10.4.7. Collaboration with CHDI
      • 5.10.4.8. Collaboration with Janssen
      • 5.10.4.9. Collaboration with MedImmune
      • 5.10.4.10. Collaboration with UCB Pharma
    • 5.10.5. Evotec Sales Forecast, 2015-2025
  • 5.11. GenScript
    • 5.11.1. GenScript: Agreements and Partnerships
  • 5.12. Pharmaceutical Product Development (PPD)
    • 5.12.1. PPD: Agreements, Strategic Partnerships and Private Merger
      • 5.12.1.1. Acquisition of Acurian
      • 5.12.1.2. Partnership with Elan
      • 5.12.1.3. Partnership with GSK
  • 5.13. Quintiles
    • 5.13.1Quintiles: Historical Revenue and Financial Performance, 2009-2013
    • 5.13.2. Development Deal With Merck
    • 5.13.3. Quintiles: Acquisition of Advion Bioanalytical Labs
    • 5.13.4. Quintiles: Shedding Jobs
    • 5.13.5. Quintiles Sales Forecast, 2015-2025
  • 5.14. Selcia
    • 5.14.1. A Strong Natural Product Chemistry Track Record
    • 5.14.2. Initiative with the University of Edinburgh
    • 5.14.3. Collaboration with Cantab
  • 5.15. Viva Biotech
    • 5.15.1. GPCR Targeted Discovery Programs
    • 5.15.2. Antibody Therapeutics Discovery
  • 5.16. WIL Research Laboratories
    • 5.16.1. Focus on Preclinical Research
    • 5.16.2. Acquisition of Ricerca Biosciences LLC
    • 5.16.3. Acquisition of Midwest BioResearch
  • 5.17. WuXi Apptec
    • 5.17.1WuXi AppTec: Service Offerings
    • 5.17.2. Acquisition of NextCODE Health
    • 5.17.3. WuXi AppTec: Historical Revenue and Financial Performance, 2009-2013
    • 5.17.4. WuXi AppTec: Laboratory Services Sales Forecast, 2015-2025

6. Qualitative Analysis of the Drug Discovery Outsourcing Market, 2015-2025

  • 6.1. Drivers and Restraints in the Drug Discovery Outsourcing Market, 2015-2025
  • 6.2. SWOT Analysis of the Drug Discovery Outsourcing Market, 2015-2025
  • 6.3. Strengths
    • 6.3.1. Cost Reduction: A Central Driver for Outsourcing
    • 6.3.2. Accelerating the Discovery of Drug Candidates
    • 6.3.3. Growth of Virtual Pharma Companies
    • 6.3.4. Reduction in R&D capacity Within Big Pharma
  • 6.4. Weaknesses
    • 6.4.1. Slowing Trajectory of Growth for R&D Spending
    • 6.4.2. Increasingly Saturated Market Requires Companies to Quickly Evolve
  • 6.5. Opportunities
    • 6.5.1. The Available Scope for the Expansion of CROs
    • 6.5.2. Targeted Therapies: Advances in Biologics and Orphan Drugs
    • 6.5.3. Increasing Development of Biologics and Biosimilars
  • 6.6. Threats
    • 6.6.1. A Competitive Market is Increasing Consolidation
    • 6.6.2. Threat of Private Public Alliances
    • 6.6.3. Intellectual Property Leaks
    • 6.6.4. Challenges of Technology Transfer
  • 6.7. Porter's Five Force Analysis of the Drug Discovery Outsourcing Market
    • 6.7.1. Threat of New Entrants: Medium
    • 6.7.2. Power of Suppliers: Medium
    • 6.7.3. Threat of Substitutes: Medium
    • 6.7.4. Power of Buyers: High
    • 6.7.5. Rivalry Among Competitors: High

7. Expert Opinions

  • 7.1. Interview with Dr Mario Polywka, Chief Operating Officer, Evotec
    • 7.1.1. Bridging the Gap Between Academia and Big Pharma
    • 7.1.2. Evotec: Specialises in Certain Disease Therapies
    • 7.1.3. Complete Drug Discovery Outsourcing: A Growing Trend
    • 7.1.4. Strategies for Drug Discovery Outsourcing Expansion
    • 7.1.5. Building Trust in Collaborations
    • 7.1.6. Evotec: Proven Track Record of Success
  • 7.2. Dr John Davis, Director of Discovery and Dave Roberts, Business Development Director, Radiochemistry, Selcia
    • 7.2.1. Growth in the Full Spectrum of Outsourcing Services
    • 7.2.2. Natural Products: Increasing Source of Drug Discovery
    • 7.2.3. Strong Pool of Early Drug Candidates
    • 7.2.4. Overcoming Drug Discovery Challenges using Drug Discovery
    • 7.2.5. Selcia: Regional Base of Clients
    • 7.2.6. Drug Discovery and Emerging Technologies
    • 7.2.7. MedChemPlus Projects
    • 7.2.8. Varied Customer Base
    • 7.2.9. CROs: Improving Drug Discovery Productivity Levels?
  • 7.3. Interview with Dr. Paul Overton, Executive VP, Business Development & Marketing, Aptuit
    • 7.3.1. End-to-End Drug Discovery Integration Growth
    • 7.3.2. Whole Project Externalisation
    • 7.3.3. Drug Discovery Outsourcing: One of Aptuit's Fastest Growing Services
    • 7.3.4. Aptuit INDiGO® Program
    • 7.3.5. Aptuit Implementation Drug Discovery Acquisitions
    • 7.3.6. Aptuit: Adding the Intellectual Capabilities for Drug Discovery
    • 7.3.7. Several Partners in the Drug Discovery Model

8. Conclusion

  • 8.1. Market Overview
  • 8.2. Lead Optimisation will be the Fastest Growing Sector
  • 8.3. The Drug Discovery Outsourcing Market in Emerging Market Show Huge Gains
  • 8.4. Continued Growth in Alliances and Collaborations
  • 8.5. Concluding Remarks

List of Tables

  • Table 1.1: The Drug Discovery Outsourcing Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2014-2025
  • Table 1.2: The Indian Drug Discovery Outsourcing Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2014-2025
  • Table 2.1: Indication of Functions Outsourced in the Different Stages of the Drug R&D Process, 2015
  • Table 2.2: Selected Drug Discovery Outsourcing Alliances, 2013-2014
  • Table 3.1: PhMRA's Historical Estimate for its Member's Total R&D Spending ($bn),1980-2013
  • Table 3.2: The Global Drug Discovery Outsourcing Market: Revenue ($bn), Market Share (%) by Sector, 2014
  • Table 3.3: The Global Drug Discovery Outsourcing Market Forecast: Revenue ($bn), AGR (%), CAGR (%) by Sector, 2014-2025
  • Table 3.4: The Global Drug Discovery Outsourcing Market: Revenue Share (%) by Sector, 2014, 2019 and 2025
  • Table 3.5: The Chemistry Services Outsourcing Market Forecast: Revenue ($bn), AGR (%), CAGR (%) by Sector, 2014-2025
  • Table 3.6: The Biology Services Outsourcing Market Forecast: Revenue ($bn), AGR (%), CAGR (%) by Sector, 2014-2025
  • Table 3.7: The Lead Optimisation Outsourcing Market Forecast: Revenue ($bn), AGR (%), CAGR (%) by Sector, 2014-2025
  • Table 3.8: Selected Source for Lead Compounds, 2015
  • Table 3.9: The Lead Identification and Screening Outsourcing Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2014-2025
  • Table 4.1: The Global Drug Discovery Outsourcing Market: Revenue ($bn), Market Share (%) by Region, 2014
  • Table 4.2: The Global Drug Discovery Outsourcing Market Forecast: Revenue ($bn), AGR (%), CAGR (%) by Region, 2014-2025
  • Table 4.3: The Global Drug Discovery Outsourcing Market: Market Share (%) by Region, 2014, 2019, 2025
  • Table 4.4: The Global Drug Discovery Outsourcing Market Forecast: CAGR (%) by Region, 2014-2019, 2019-2025, 2014-2025
  • Table 4.5: The US Drug Discovery Outsourcing Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2014-2025
  • Table 4.6: The US Drug Discovery Outsourcing Market Forecast: Market Size ($bn), Rank, Market Share (%) and CAGR (%), 2014-2025
  • Table 4.7: The EU5 Drug Discovery Outsourcing Market: Revenue ($m), Market Share (%) by Region, 2014
  • Table 4.8: The EU5 Drug Discovery Outsourcing Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2014-2025
  • Table 4.9: The EU5 Drug Discovery Outsourcing Market Forecast: CAGR (%) by Country, 2014-2019, 2019-2025, and 2014-2025
  • Table 4.10: The EU5 Drug Discovery Outsourcing Market: Market Shares (%) by Country, 2014, 2019, 2025
  • Table 4.11: The German Drug Discovery Outsourcing Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2014-2025
  • Table 4.12: The German Drug Discovery Outsourcing Market Forecast: Market Size ($bn), Rank, Market Share (%) and CAGR (%), 2014-2025
  • Table 4.13: The UK Drug Discovery Outsourcing Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2014-2025
  • Table 4.14: The UK Drug Discovery Outsourcing Market Forecast: Market Size ($bn), Rank, Market Share (%) and CAGR (%), 2014-2025
  • Table 4.15: The French Drug Discovery Outsourcing Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2014-2025
  • Table 4.16: The French Drug Discovery Outsourcing Market Forecast: Market Size ($bn), Rank, Market Share (%) and CAGR (%), 2014-2025
  • Table 4.17: The Italian Drug Discovery Outsourcing Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2014-2025
  • Table 4.18: The Italian Drug Discovery Outsourcing Market Forecast: Market Size ($bn), Rank, Market Share (%) and CAGR (%), 2014-2025
  • Table 4.19: The Spanish Drug Discovery Outsourcing Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2014-2025
  • Table 4.20: The Spanish Drug Discovery Outsourcing Market Forecast: Market Size ($bn), Rank, Market Share (%) and CAGR (%), 2014-2025
  • Table 4.21: The Japanese Drug Discovery Outsourcing Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2014-2025
  • Table 4.22: The Japanese Drug Discovery Outsourcing Market Forecast: Market Size ($bn), Rank, Market Share (%) and CAGR (%), 2014-2025
  • Table 4.23: The Chinese Drug Discovery Outsourcing Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2014-2025
  • Table 4.24: The Chinese Drug Discovery Outsourcing Market Forecast: Market Size ($bn), Rank, Market Share (%) and CAGR (%), 2014-2025
  • Table 4.25: The Indian Drug Discovery Outsourcing Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2014-2025
  • Table 4.26: The Indian Drug Discovery Outsourcing Market Forecast: Market Size ($bn), Rank, Market Share (%) and CAGR (%), 2014-2025
  • Table 4.27: The Brazilian Drug Discovery Outsourcing Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2014-2025
  • Table 4.28: The Brazilian Drug Discovery Outsourcing Market Forecast: Market Size ($bn), Rank, Market Share (%) and CAGR (%), 2014-2025
  • Table 4.29: The Russian Drug Discovery Outsourcing Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2014-2025
  • Table 4.30: The Russian Drug Discovery Outsourcing Market Forecast: Market Size ($bn), Rank, Market Share (%) and CAGR (%), 2014-2025
  • Table 4.31: The South Korean Drug Discovery Outsourcing Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2014-2025
  • Table 4.32: The South Korean Drug Discovery Outsourcing Market Forecast: Market Size ($bn), Rank, Market Share (%) and CAGR (%), 2014-2025
  • Table 4.33: The Mexican Drug Discovery Outsourcing Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2014-2025
  • Table 4.34: The Mexican Drug Discovery Outsourcing Market Forecast: Market Size ($bn), Rank, Market Share (%) and CAGR (%), 2014-2025
  • Table 4.35: The Rest of the World Drug Discovery Outsourcing Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2014-2025
  • Table 5.1: Albany Molecular Research (AMRI): Historical Revenue ($m), AGR (%), 2011-2013
  • Table 5.2: AMRI: Service Offerings and Descriptions, 2015
  • Table 5.3: AMRI: Drug Discovery and Development Programmes and Project Stage
  • Table 5.4: AMRI (DDS) Forecast: Revenue ($m), AGR (%), CAGR (%), 2014-2025
  • Table 5.5: Aptuit: Services Offered and their Descriptions, 2015
  • Table 5.6: Charles River Laboratories: Services Offered by Segment, 2015
  • Table 5.7: Charles River Laboratories: Revenue ($m), AGR (%), 2011-2013
  • Table 5.8: Charles River Laboratories: Revenue ($m) by Segment, 2011-2013
  • Table 5.9: Charles River Laboratories: Revenue ($bn) by Business Segment, 2013-2014
  • Table 5.10: Charles River Laboratories Forecast: Revenue ($m), AGR (%), CAGR (%), 2014-2025
  • Table 5.11: Covance: Historical Revenue ($bn) by Business Segment, 2010-2013
  • Table 5.12: Selected Cyprotex Partnerships, 2015
  • Table 5.13: Cyprotex: Historical Revenue ($m), (£m), AGR (%), 2011-2013
  • Table 5.14: Cyprotex: Revenue ($m), Revenue Share (%) by Region, 2013
  • Table 5.15: Cyprotex Forecast: Revenue ($m), AGR (%), CAGR (%), 2014-2025
  • Table 5.16: Cyprotex Forecast: Revenue ($m), AGR (%), CAGR (%), 2014-2025
  • Table 5.17: Evotec: Historical Revenue ($m), (€m), AGR(%), 2010-2013
  • Table 5.18: Evotec: Discovery Pipeline, 2015
  • Table 5.19: Evotec Forecast: Revenue ($m), AGR (%), CAGR (%), 2014-2025
  • Table 5.20: GenScript: Services Offered and Descriptions, 2015
  • Table 5.21: Quintiles: Revenue ($bn), AGR (%), 2009-2013
  • Table 5.22: Quintiles Forecast: Revenue ($bn), AGR (%), CAGR (%), 2014-2025
  • Table 5.23: Selcia: Drug Discovery Services Portfolio, 2015
  • Table 5.24: Viva Biotech: Service Offerings, 2015
  • Table 5.25: WuXi AppTec: Pharmaceutical Laboratory Services and Descriptions, 2015
  • Table 5.26: WuXi AppTec: Historical Revenue ($m), AGR (%) by Business Segment, 2009-2013
  • Table 5.27: WuXi AppTec Laboratory Services Forecast: Revenue ($m), AGR (%), CAGR (%), 2014-2025
  • Table 6.1: SWOT Analysis of the Drug Discovery Outsourcing Industry, 2015-2025
  • Table 8.1: The Global Drug Discovery Outsourcing Market Forecast: Revenue ($bn), CAGR (%), 2014, 2019, 2025
  • Table 8.2: The Global Drug Discovery Outsourcing Market: Revenue ($bn) by Sector, 2014, 2019, 2025
  • Table 8.3: The Drug Discovery Outsourcing Market Forecast: Revenue ($bn) by Emerging Market, 2014, 2019 and 2025

List of Figures

  • Figure 1.1: The Drug Discovery Outsourcing Market: Overview of Submarkets
  • Figure 2.1: Selected Tasks being Outsourced in the Pharma Industry, 2015
  • Figure 2.2: Stages of the Drug Development Cycle
  • Figure 3.1: PhMRA's Historical Estimate for its Member's Total R&D Spending ($bn), 1980-2013
  • Figure 3.2: Attrition Rate of Compounds at the Developmental Stages
  • Figure 3.3: The Global Drug Discovery Outsourcing Market: Revenue ($bn) by Sector, 2014
  • Figure 3.4: The Global Drug Discovery Outsourcing Market: Market Share (%) by Sector, 2014
  • Figure 3.5: The Global Drug Discovery Outsourcing Market Forecast: Revenue ($bn), AGR (%), 2014-2025
  • Figure 3.6: The Global Drug Discovery Outsourcing Market: Market Shares (%) by Sector, 2019
  • Figure 3.7: The Global Drug Discovery Outsourcing Market: Market Shares (%) by Sector, 2025
  • Figure 3.8: The Chemistry Services Outsourcing Market Forecast: Revenue ($bn), AGR (%), 2014-2025
  • Figure 3.9: The Biology Services Outsourcing Market Forecast: Revenue ($bn), AGR (%), 2014-2025
  • Figure 3.10: An Overview of ADMET Screening in Drug Discovery
  • Figure 3.11: The Lead Optimisation Outsourcing Market Forecast: Revenue ($bn), AGR (%), 2014-2025
  • Figure 3.12: Typical Steps in the Lead Screening Process
  • Figure 3.13: The Lead Identification and Screening Outsourcing Market Forecast: Revenue ($bn), AGR (%), 2014-2025
  • Figure 4.1: The Global Drug Discovery Outsourcing Market: Revenue ($bn) by Region, 2014
  • Figure 4.2: The Global Drug Discovery Outsourcing Market: Market Share (%) by Region, 2014
  • Figure 4.3: The Global Drug Discovery Outsourcing Market: Market Share (%) by Region, 2019
  • Figure 4.4: The Global Drug Discovery Outsourcing Market: Market Share (%) by Region, 2025
  • Figure 4.5: The Global Drug Discovery Outsourcing Market Forecast: CAGR (%) by Region, 2014-2019
  • Figure 4.6: The Global Drug Discovery Outsourcing Market Forecast: CAGR (%) by Region, 2019-2025
  • Figure 4.7: The Global Drug Discovery Outsourcing Market Forecast: CAGR (%) by Region, 2014-2025
  • Figure 4.8: The US Drug Discovery Outsourcing Market Forecast: Revenue ($bn), AGR (%), 2014-2025
  • Figure 4.9: The EU5 Drug Discovery Outsourcing Market: Market Revenue ($m) by Region, 2014
  • Figure 4.10: The EU5 Drug Discovery Outsourcing Market: Market Share (%) by Region, 2014
  • Figure 4.11: The EU5 Drug Discovery Outsourcing Market Forecast: Revenue ($m), AGR (%), 2014-2025
  • Figure 4.12: The EU5 Drug Discovery Outsourcing Market Forecast: CAGR (%) by Country, 2014-2019
  • Figure 4.13: The EU5 Drug Discovery Outsourcing Market Forecast: CAGR (%) by Country, 2019-2025
  • Figure 4.14: The EU5 Drug Discovery Outsourcing Market Forecast: CAGR (%) by Country, 2014-2025
  • Figure 4.15: The EU5 Drug Discovery Outsourcing Market Forecast: Market Shares (%) by Country, 2019
  • Figure 4.16: The EU5 Drug Discovery Outsourcing Market Forecast: Market Shares (%) by Country, 2025
  • Figure 4.17: The German Drug Discovery Outsourcing Market Forecast: Revenue ($m), AGR (%), 2014-2025
  • Figure 4.18: The UK Drug Discovery Outsourcing Market Forecast: Revenue ($m), AGR (%), 2014-2025
  • Figure 4.19: The French Drug Discovery Outsourcing Market Forecast: Revenue ($m), AGR (%), 2014-2025
  • Figure 4.20: The Italian Drug Discovery Outsourcing Market Forecast: Revenue ($m), AGR (%), 2014-2025
  • Figure 4.21: The Spanish Drug Discovery Outsourcing Market Forecast: Revenue ($m), AGR (%), 2014-2025
  • Figure 4.22: The Japanese Drug Discovery Outsourcing Market Forecast: Revenue ($bn), AGR (%), 2014-2025
  • Figure 4.23: The Chinese Drug Discovery Outsourcing Market Forecast: Revenue ($bn), AGR (%), 2014-2025
  • Figure 4.24: The Chinese Population Demographics: Over 65 population and Forecast (millions), 1950, 2010, 2050
  • Figure 4.25: The Indian Drug Discovery Outsourcing Market Forecast: Revenue ($bn), AGR (%), 2014-2025
  • Figure 4.26: The Brazilian Drug Discovery Outsourcing Market Forecast: Revenue ($bn), AGR (%), 2014-2025
  • Figure 4.27: The Russian Drug Discovery Outsourcing Market Forecast: Revenue ($bn), AGR (%), 2014-2025
  • Figure 4.28: The South Korean Drug Discovery Outsourcing Market Forecast: Revenue ($bn), AGR (%), 2014-2025
  • Figure 4.29: The Mexican Drug Discovery Outsourcing Market Forecast: Revenue ($bn), AGR (%), 2014-2025
  • Figure 4.30: The Rest of the World Drug Discovery Outsourcing Market Forecast: Revenue ($bn), AGR (%), 2014-2025
  • Figure 5.1: Albany Molecular Research (AMRI): Historical Revenue ($m), AGR (%), 2010-2013
  • Figure 5.2: AMRI (DDS) Forecast: Revenue ($m), AGR (%), 2014-2025
  • Figure 5.3: Charles River Laboratories: Revenue ($m), AGR (%), 2011-2013
  • Figure 5.4: Charles River Laboratories: Revenue Share (%) by Segment, 2013
  • Figure 5.5: Charles River Laboratories: Revenue ($bn), 2013-2014
  • Figure 5.6: Charles River Laboratories: Revenue Share (%) by Business Segment, 2014
  • Figure 5.7: Charles River Laboratories Forecast: Revenue ($m), AGR (%), 2014-2025
  • Figure 5.8: Covance: Historical Revenue ($bn), 2010-2013
  • Figure 5.9: Covance: Revenue Share (%) by Segment, 2013
  • Figure 5.10: Cyprotex: Historical Revenue (£m), AGR (%), 2011-2013
  • Figure 5.11: Cyprotex: Revenue Share (%) by Region, 2013
  • Figure 5.12: Cyprotex Forecast: Revenue ($m), AGR (%), 2014-2025
  • Figure 5.13: Domainex: Drug Pipeline by Indication, 2015
  • Figure 5.14: Evotec: Historical Revenue (€m), AGR (%), 2010-2013
  • Figure 5.15: Evotec Forecast: Revenue ($m), AGR (%), 2014-2025
  • Figure 5.16: Quintiles: Historical Revenue ($bn), AGR (%), 2009-2013
  • Figure 5.17: Quintiles Forecast: Revenue ($bn), AGR (%), 2014-2025
  • Figure 5.18: WuXi AppTec: Historical Revenue ($m) by Business Segment, 2009-2013
  • Figure 5.19: WuXi AppTec Laboratory Services Forecast: Revenue ($m), AGR (%), 2014-2025
  • Figure 6.1: The Drug Discovery Outsourcing Market: Drivers and Restraints, 2015-2025
  • Figure 6.2: Porter's Five Analysis of the Companion Diagnostics Market, 2015-2025
  • Figure 8.1: The Global Drug Discovery Outsourcing Market Forecast: Revenue ($bn), 2014, 2019, 2025
  • Figure 8.2: The Global Drug Discovery Outsourcing Market Forecast: Revenue ($bn) by Sector, 2014, 2019, 2025
  • Figure 8.3: The Drug Discovery Outsourcing Market Forecast: Revenue ($bn) by Emerging Market, 2014, 2019 and 2025

Companies Listed

  • AbbVie
  • Actavis
  • Acurian
  • ADDC
  • Advion Bioanalytical Labs
  • Albany Molecular Research (AMRI)
  • Alexion
  • AMRI
  • Apredica
  • Aptuit
  • Argenta
  • Ark Therapeutics
  • AstraZeneca
  • Auspherix
  • Bayer
  • Behrman Capital
  • Bio City
  • BioDuro
  • BioFocus
  • BioPontis Alliance
  • Boehringer Ingelheim Pharmaceuticals
  • Bristol Myers Squibb
  • C4X Discovery (C4XD)
  • Cantab
  • Caprion Proteomics
  • Catalent Pharma Solutions
  • ChanTest
  • Charles River Laboratories
  • CHDI Foundation
  • ChemBridge
  • ChemDiv
  • Convergence Pharmaceuticals
  • Covance
  • LabCorp
  • CRL
  • CTSI
  • Cyprotex
  • Daiichi Sankyo
  • Domainex
  • Synthesis Med Chem
  • Elan
  • Eli Lilly
  • Enamine
  • Evotec
  • Fidelity Growth Partners India (FGPI)
  • Forma Therapeutics
  • Fraunhofer Institute for Molecular Biology and Applied Ecology
  • Galapagos
  • GE Healthcare
  • Genentech
  • GenScript
  • Great Lakes Chemical Corp
  • GSK
  • HD Biosciences
  • Horizon
  • Hypha Discovery
  • ICON
  • IMI
  • Immatics
  • Janssen Pharmaceuticals
  • Johnson & Johnson Innovation
  • KDDF
  • Kellogg Company
  • Knopp Biosciences
  • LabCorp
  • Laurus Labs
  • Marshall University
  • MedImmune
  • Merck
  • Midwest BioResearch
  • MRC Technology
  • NextCODE Health
  • Ono
  • Oxford Asymmetry International
  • Parexel
  • Pharmaceutical Product Development (PPD)
  • Proteros
  • Quintiles
  • Ricerca Biosciences LLC
  • Roche
  • Rules-Based Medicines
  • Sanofi
  • Scynexis Europe
  • Selcia
  • ShangPharma Corporation
  • Shire US Manufacturing Inc
  • Siena Biotech
  • SmithKline Beecham
  • Tigermed Consulting
  • UC San Francisco (UCSF)
  • UCB Pharma
  • Viva Biotech
  • VivoPath
  • WCCT Global
  • WIL Research Laboratories
  • WuXi AppTec
  • X-Chem

Other Organisations Mentioned in This Report

  • ABO
  • Academic Consortium: St George's, University of Manchester
  • Academy of Military Medical Sciences
  • Beijing Genomics Institute
  • Biomedical Catalyst Fund
  • Bundesverband Medizinischer Auftragsinstitute (BVMA)
  • Cambridge University
  • Dundee University
  • Indiana Clinical and Translational Sciences Institute (CTSI)
  • Innovative Medicine Initiative (IMI)
  • JOINN Laboratories
  • National Centre of Biomedical Analysis
  • National Institute for Food and Drug Control
  • North Carolina University
  • PhRMA (Pharmaceutical Research and Manufacturers of America)
  • The European CRO Federation (EUCROF)
  • The Food and Drug Administration FDA (U.S)
  • The Korea Drug Development Fund (KDDF)
  • The Royal Society of Chemistry
  • The Russian Corporation of Nanotechnologies
  • The University of Edinburgh
  • The University of Oxford
  • The Wellcome Trust
  • University of North Carolina
  • US National Institutes of Health (NIH)
Back to Top